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Leishmania donovani is an obligate intracellular parasite that infects macrophages of the vertebrate host resulting in visceral leishman-
iasis in humans, a major public health problem worldwide. The molecular mechanisms involved in internalization of Leishmania are still
poorly characterized. We report here that cholesterol sequestration by the sterol-binding antifungal polyene antibiotic nystatin markedly
inhibits binding and entry of non-opsonized L. donovani promastigotes into macrophages. Interestingly, these effects are not observed
when serum-opsonized L. donovani are used for infectivity studies thus pointing the essential role of cholesterol in mediating entry of
the parasite via the non-opsonic pathway. Based on our earlier results where leishmanial infectivity was shown to be sensitive to physical
depletion of cholesterol from macrophages, these results indicate that the mere sequestration of cholesterol in the host plasma membrane
is sufficient to inhibit the binding and entry of non-opsonized L. donovani. These results represent the first report on the effect of a cho-
lesterol-sequestering agent on the entry of Leishmania parasites to host macrophages. More importantly, these findings offer the possi-
bility of reevaluating the mechanism behind the effectiveness of current therapeutic strategies to treat leishmaniasis.
 2005 Elsevier Inc. All rights reserved.
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caused by the protozoan parasite Leishmania donovani [1].
The estimated annual number of new cases of visceral leish-
maniasis is about 500,000 [1]. The current increase in leish-
maniasis throughout the world to epidemic proportion
coupled with increasing incidence of the disease in devel-
oped countries, and emergence of visceral leishmaniasis
as an important opportunistic infection among people with
human immunodeficiency-1 (HIV-1) infection [2] have cre-
ated an urgency to provide treatment for this intracellular
infection. Leishmania are digenetic protozoan parasites
and exist either as extracellular promastigotes that reside0006-291X/$ - see front matter  2005 Elsevier Inc. All rights reserved.
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E-mail address: madhubala@mail.jnu.ac.in (R. Madhubala).in the mid-gut of sandflies or as intracellular amastigotes
adapted for survival within phagolysosomes of mammalian
macrophages. Entry of promastigotes into macrophages
involves recognition of specific ligands on the parasite cell
surface by receptors on the macrophage cell surface and the
subsequent internalization of the parasite by the macro-
phage. Studies on the molecular mechanisms of parasite
entry have led to the identification of several candidate
receptors facilitating multiple routes of entry thereby high-
lighting the redundancy in the entry process [3]. These
include membrane proteins present on the macrophage cell
surface such as the mannose–fucose receptor, receptor for
advanced glycosylation end products, the fibronectin recep-
tor, the Fc receptor (FcR), and the complement receptors
such as the CR1 and CR3. The large number of different
receptors responsible for the entry of the parasite into host
macrophages makes it difficult to have a unique therapeutic
target for the treatment of leishmaniasis.
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other intracellular parasites in general involves interaction
with the plasma membrane of host cells. Cholesterol is a
major constituent of the eukaryotic plasma membrane.
The essential role of cholesterol in maintaining membrane
protein function is well established [4]. This is proposed to
occur either due to a specific local molecular interaction
with membrane proteins, or due to alterations in the mem-
brane physical properties induced by the presence of cho-
lesterol [4–7], or due to a combination of both factors.
We have recently shown the requirement of host membrane
cholesterol in the binding and internalization of Leishmania
promastigotes into macrophage cells [8]. This was achieved
by the use of methyl-b-cyclodextrin (MbCD) which physi-
cally depletes cholesterol from membranes [9,10]. Treat-
ment of macrophages in culture with MbCD resulted in
the specific removal of membrane cholesterol and a con-
comitant reduction in binding and subsequent infection
by Leishmania promastigotes [8]. If cholesterol is necessary
for leishmanial infection, modulating cholesterol availabil-
ity by other means could affect leishmanial infection. In
this report, we have tested this proposal by treating macro-
phages with the sterol-binding antifungal polyene antibiot-
ic nystatin [11–13]. Nystatin specifically interacts with
cholesterol to sequester it in the membrane thereby effec-
tively reducing the ability of cholesterol to interact with
and exert its effects on other membrane components such
as receptors. Our results show that sequestration of choles-
terol in the macrophage membrane without its physical
depletion is sufficient to inhibit leishmanial infection.
Although nystatin has earlier been used on isolated leish-
mania parasites [14,15], this is the first report describing
the effect of nystatin treatment of host macrophages on
leishmanial infection.
Materials and methods
Materials. RPMI-1640 medium, M-I99 medium, penicillin, strepto-
mycin, nystatin, MbCD, and FITC were obtained from Sigma Chemical
(St. Louis, MO, USA). Fetal calf serum was obtained from Gibco/BRL
Life Technologies (Scotland, UK). Radiolabeled [3H]thymidine was
obtained from Dupont New England Nuclear (Boston, MA, USA).
Cells and cell culture. The murine macrophage J774A.1 (American
Type Culture Collection) cells were maintained at 37 C in RPMI-1640
medium supplemented with 100 U/ml penicillin, 100 lg/ml streptomycin,
and 10% heat-inactivated fetal calf serum [8].
Parasite culture. Leishmania donovani strain AG83 (MHOM/IN/1983/
AG83) parasites were maintained as promastigotes at 22 C in modified
M-199 medium supplemented with 100 U/ml and 100 lg/ml streptomycin
and 10% heat inactivated fetal calf serum as described previously [16].
Cholesterol sequestration of macrophages. Cholesterol sequestration
was carried out by incubating J774A.1 cells with nystatin in serum-free
RPMI-1640 medium at 37 C for 30 min followed by a wash with PBS
before being exposed to parasites. Macrophages were plated at a density of
1 · 105 in 35 mm culture dishes and grown for 48 h for radiolabeled or
FITC-labeled parasite-binding experiments. For Giemsa staining experi-
ments, macrophages were plated at a density of 5 · 105 in 60 mm dishes
and grown for 24 h.
Radiolabeling L. donovani promastigotes with tritium or FITC for
binding studies. Parasites were metabolically radiolabeled with tritium as
described previously [17] with some modifications. Radiolabel incorpo-ration was carried out at a density of 1 · 107 parasites/2 ml M-199
medium in the presence of 20 lCi/ml [3H]thymidine (sp. activi-
ty = 89.4 Ci/mmol) at 22 C for 3 h. FITC-labeling of parasites was car-
ried out as described previously [18], except that labeling was carried out
37 C in phosphate-buffered saline (PBS).
Opsonization of L. donovani promastigotes. Opsonization was carried
out as described earlier [19], with few modifications. Promastigotes were
first radiolabeled with 20 lCi/ml [3H]thymidine as described above.
Radiolabeled promastigotes were suspended in mouse serum at a density
of 1 · 108 cells/ml at 37 C for 25 min in PBS. Opsonized parasites were
washed once with PBS and used directly.
Infectivity assays. Promastigotes were added onto macrophage mon-
olayers at a parasite to macrophage ratio of 10:1 in RPMI-1640 medium at
37 C for the indicated time periods. At the end of incubation, monolayers
were washed twice with PBS to remove free parasites, solubilized with 1%
Triton X-100, and assayed for radioactivity using a Packard Tri-Carb
liquid scintillation counter. In flow cytometric experiments, FITC-labeled
parasites were used to infect macrophages for the indicated time periods.
After infection, macrophages were gently scraped into PBS with 0.1%
formaldehyde at 4 C. The fluorescence from FITC-labeled parasites
associated with 5000–10,000 macrophages was analyzed with a Beckman
Coulter ELITE ESP flow cytometer using EXPO 32 software for data
analysis. To assess the percentage of macrophages harboring the intra-
cellular amastigote form of the parasite, macrophages were exposed to the
parasites for a period of 3 h after which cell monolayers were stained with
Giemsa. The number of amastigotes in macrophages was visually scored
using a Leica microscope with a 100· oil-immersion objective.Results
We monitored the effect of treating host J774A.1 macro-
phages with nystatin on the binding of Leishmania promas-
tigotes. As mentioned earlier, nystatin specifically interacts
with cholesterol [11–13] to sequester it in the membrane
thereby effectively reducing the ability of cholesterol to
interact with other membrane constituents such as recep-
tors. In these experiments, macrophages were incubated
with increasing concentrations of nystatin, followed by a
wash to remove any unbound nystatin before being
exposed to Leishmania parasites. In order to analyze the
effect of nystatin treatment on the ability of Leishmania
to infect macrophages, radioligand-binding assays with
[3H]thymidine-labeled non-opsonized parasites were car-
ried out. As shown in Fig. 1A, treatment of macrophages
with increasing concentrations of nystatin progressively
reduces the binding of parasites to macrophages. Thus, a
concentration of 25 lg/ml nystatin gives rise to 50%
reduction in macrophage-parasite interaction. The effect
of nystatin treatment was further analyzed by monitoring
the kinetics of macrophage–parasite interaction. As shown
in Fig. 1B, macrophages pretreated with 25 lg/ml nystatin,
when used as hosts against the parasite, display a time-de-
pendent reduction in macrophage–parasite interaction with
60% reduction when infection was monitored for
180 min.
The entry of Leishmania into macrophages has been
attributed to multiple receptor-mediated mechanisms
involving several macrophage cell surface receptors. These
include receptors such as the CR1 and CR3, the mannose–
fucose receptor, the fibronectin receptor, the receptor for
advanced glycosylation end products, the Fc receptor,
Fig. 1. Effect of cholesterol sequestration by nystatin on the extent and
kinetics of binding of Leishmania promastigotes to host macrophages. (A)
The extent of binding of radiolabeled non-opsonized promastigotes to
macrophages with increasing concentrations of nystatin (NYS) is shown.
Macrophages were exposed to radiolabeled parasites for 90 min at a
parasite to macrophage ratio of 10:1. All values are normalized with
respect to the mean counts per minute obtained for control cells. The data
shown are means ± SD of two independent experiments performed in
duplicate. (B) The kinetics of binding of radiolabeled non-opsonized
Leishmania promastigotes to control (white bars) and nystatin-treated
(gray bars) macrophages is shown. Macrophages were pretreated with
nystatin at a concentration of 25 lg/ml. All values are normalized with
respect to the mean counts per minute obtained for control cells after
30 min exposure to the parasite. The data shown are means ± SD of two
independent experiments performed in duplicate. See Materials and
methods for other details.
Fig. 2. Comparison of the effect of cholesterol sequestration by nystatin
on the binding of non-opsonized and opsonized Leishmania promastigotes
to host macrophages. Control (white bars) or nystatin-treated (gray bars)
macrophages were exposed to radiolabeled parasites for 90 min at a
parasite to macrophage ratio of 10:1. Macrophages were pretreated with
nystatin at a concentration of 25 lg/ml. All values are normalized with
respect to the mean counts per minute obtained for the respective controls
in the experiment. The data shown are means ± SD of two independent
experiments performed in duplicate. See Materials and methods for other
details.
P. Tewary et al. / Biochemical and Biophysical Research Communications 339 (2006) 661–666 663and the C-reactive protein receptor. Serum-opsonized par-
asites are considered to predominantly bind to the CR1
and CR3 receptors on the macrophage cell surface and
accomplish infection [3]. To further understand the reduced
infectivity of Leishmania promastigotes in cholesterol-se-
questered macrophages, we carried out binding studies
with radiolabeled promastigotes which were opsonized
with mouse serum. Fig. 2 shows that while binding of
non-opsonized Leishmania to macrophages is reduced by
50% upon treatment with 25 lg/ml nystatin (similar to
that seen in Fig. 1A), binding of opsonized Leishmania
under similar conditions does not show any significant
reduction. This result shows that cholesterol sequestrationdoes not affect the route of entry undertaken by opsonized
parasites. This is similar to our previous result in which we
showed that the entry of opsonized Leishmania parasites
into macrophages is insensitive to cholesterol depletion
by MbCD [8]. Taken together, these results point out the
commonality in the underlying mechanism associated with
the inhibition in entry of non-opsonized parasites into mac-
rophages which is a result of non-availability of membrane
cholesterol. Importantly, the actual means by which mem-
brane cholesterol is made unavailable (physical depletion
using MbCD or sequestration by nystatin) therefore does
not appear to be crucial for the observed reduction in
infectivity.
We confirmed our results obtained with radioligand-
binding experiments (Figs. 1 and 2) with flow cytometric
analysis of binding of FITC-labeled promastigotes to mac-
rophages. Fluorescent derivatization of promastigotes with
FITC has previously been used as a convenient tool to
accurately monitor host–parasite interaction and provides
an ideal means for studying cell surface interaction phe-
nomena since each cell is analyzed individually for its abil-
ity to bind to a fluorescent ligand which in this case is the
FITC-labeled promastigote [18]. Data shown in Fig. 3A
reveal a time-dependent reduction in fluorescence associat-
ed with nystatin-treated macrophages as compared to con-
trol macrophages when infection is allowed to progress for
a period of 90 min. These data support our earlier conclu-
sion (from Fig. 1) of a reduction in the ability of non-opso-
nized Leishmania promastigotes to interact with the host
upon sequestration of host membrane cholesterol. Howev-
er, similar analysis carried out with opsonized promasti-
gotes (see Fig. 3B) shows no significant difference in
binding of the parasite to nystatin-treated macrophages
Fig. 3. Flow cytometric analysis of the effect of cholesterol sequestration
by nystatin on the kinetics of binding of FITC-labeled non-opsonized and
opsonized Leishmania promastigotes to host macrophages. Control (open
circles) or nystatin-treated (closed circles) macrophages were exposed to
non-opsonized (A) or opsonized (B) FITC-labeled promastigotes at a
parasite to macrophage ratio of 10:1. Macrophages were pretreated with
nystatin at a concentration of 25 lg/ml. The data are representative of two
independent experiments performed in duplicate. See Materials and
methods for other details.
Fig. 4. Effect of cholesterol sequestration by nystatin on the intracellular
amastigote load of Leishmania parasite in host macrophages. The count of
the intracellular amastigote form of the parasite is shown in macrophages
either untreated or treated with increasing concentrations of nystatin
(NYS). Macrophages pretreated with nystatin were exposed to non-
opsonized promastigotes at a parasite to macrophage ratio of 10:1 for 3 h.
The data shown are means ± SE of three independent experiments
performed in duplicate. See Materials and methods for other details.
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ment with the results obtained with radiolabeled parasites
(shown in Fig. 2).
The fact that binding of opsonized Leishmania to nysta-
tin-treated macrophages remains unaffected serves as an
important control to suggest that the effect of cholesterol
sequestration on the binding of non-opsonized parasite is
not due to a general loss of viability of macrophages after
nystatin treatment. This further helps stringently define the
specificity of interaction of the non-opsonized form of the
parasite with the host cell membrane. In a control experi-
ment, we monitored the effect of nystatin treatment of mac-
rophages on the uptake of another microbe, namely
Escherichia coli DH5a, under similar conditions as those
used for Leishmania promastigotes. In sharp contrast to
what is observed with Leishmania, flow cytometric analysis
of the binding of FITC-labeled E. coli to control and
nystatin-treated J774A.1 cells did not show any significantdifference (data not shown). This points to the specificity of
cholesterol-dependent interaction between Leishmania pro-
mastigotes and the host cell membrane.
The above results demonstrate that cholesterol seques-
tration leads to a reduction in the ability of non-opsonized
promastigotes to bind to host macrophages. For efficient
infection, binding of the parasite should be followed by
internalization. During the course of infection, the reduced
binding of the promastigotes should manifest in a reduc-
tion in the intracellular load of amastigotes, the intracellu-
lar form of the parasite present in macrophages. The
number of amastigotes after 3 h of exposure of the parasite
to nystatin-treated macrophages was determined visually
after staining the infected macrophages with Giemsa. As
shown in Fig. 4, treatment of macrophages with nystatin
results in a concentration-dependent reduction in the num-
ber of intracellular amastigotes present (compared to con-
trol cells) with a 40% reduction in the amastigotes load
when macrophages pretreated with 25 lg/ml nystatin were
used as host.
Discussion
This report represents one of the first studies on the
effect of agents that perturb membrane cholesterol on the
binding of Leishmania parasites to host macrophages. As
mentioned earlier, although nystatin has previously been
reported to possess leishmanicidal property [14,15], this is
the first report that describes the effect of treatment of host
macrophages with nystatin on leishmanial infectivity. We
have recently shown that the physical depletion of choles-
terol from macrophages leads to inhibition in the binding
and internalization of Leishmania promastigotes into mac-
rophage cells [8]. Our present results with the use of the ste-
rol-binding agent nystatin, which does not deplete
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tion of host plasma membrane cholesterol is sufficient to
inhibit leishmanial infection. Sequestration of membrane
cholesterol with nystatin could lead to a reduction in the
availability of free cholesterol in the host plasma mem-
brane essential for parasite entry (see later). Taken togeth-
er, these results reinforce the crucial requirement of
membrane cholesterol in host cells for leishmanial
infection.
The molecular mechanism of how cholesterol supports
binding of the parasite and its entry into host macrophages
remains a key issue and requires further investigation.
Interestingly, the effects of cholesterol sequestration are
abrogated when serum-opsonized parasites are used in sim-
ilar experiments as carried out for non-opsonized parasites.
This points toward the essential role of cholesterol in sup-
porting entry of the parasite via the non-opsonic pathway
into macrophages. The involvement of multiple mem-
brane-bound receptors in the entry of the parasite into host
cells has been mentioned earlier [3]. The modulatory role of
cholesterol, an essential component in the plasma mem-
brane of eukaryotic cells, on the function of membrane
receptors, such as the oxytocin receptor [4] and the seroto-
nin1A receptor [10,20], has been previously demonstrated.
These results show that perturbing the cholesterol content
and/or availability in the membrane may lead to perturba-
tion of receptor–cholesterol interactions leading to loss of
receptor function.
Cholesterol is believed to modulate organization of lip-
ids and proteins in the cell membrane [21]. It is often found
distributed non-randomly in domains in membranes [22].
Recent observations suggest that cholesterol exerts many
of its actions by maintaining putative membrane domains
termed ‘‘lipid rafts’’ in a functional state [23]. Lipid rafts
are thought of as lateral organizations on the plane of
the membrane that are enriched in cholesterol and sphingo-
lipids and specific proteins that act as receptors for the
entry of microorganisms. As a result, pathogen entry into
cells is thought to be dependent on the integrity of such
regions of the membrane [24]. Importantly, cholesterol
complexing agents such as nystatin have previously been
shown to affect the integrity of such domains and the func-
tion of membrane proteins localized in them [25,26]. It is
possible that the reduction in Leishmania infection upon
nystatin treatment is due to alterations in the function
and organization of one or more of the many receptors
on the host cell surface that participate in parasite attach-
ment and internalization [3].
On a broader perspective, our results offer the possibility
of reevaluating the mechanism behind the effectiveness of
current therapeutic strategies to treat leishmaniasis.
Among the popular clinically prescribed therapeutic drugs
to treat visceral leishmaniasis is amphotericin B [27,28] that
like nystatin is another sterol-binding antibiotic [11,13].
Although the development of amphotericin B as a therapy
against leishmaniasis has its origin in the discovery that it is
a potent leishmanicidal agent [29,30], it is possible that itseffectiveness in vivo is partly based on its ability, like nys-
tatin, to sequester cholesterol in the host membrane there-
by reducing macrophage–parasite interaction.Acknowledgments
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